Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets
- PMID: 36926666
- PMCID: PMC10011951
- DOI: 10.3748/wjg.v29.i7.1157
Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets
Abstract
Mucosal healing (MH) is vital in maintaining homeostasis within the gut and protecting against injury and infections. Multiple factors and signaling pathways contribute in a dynamic and coordinated manner to maintain intestinal homeostasis and mucosal regeneration/repair. However, when intestinal homeostasis becomes chronically disturbed and an inflammatory immune response is constitutively active due to impairment of the intestinal epithelial barrier autoimmune disease results, particularly inflammatory bowel disease (IBD). Many proteins and signaling pathways become dysregulated or impaired during these pathological conditions, with the mechanisms of regulation just beginning to be understood. Consequently, there remains a relative lack of broadly effective therapeutics that can restore MH due to the complexity of both the disease and healing processes, so tissue damage in the gastrointestinal tract of patients, even those in clinical remission, persists. With increased understanding of the molecular mechanisms of IBD and MH, tissue damage from autoimmune disease may in the future be ameliorated by developing therapeutics that enhance the body's own healing response. In this review, we introduce the concept of mucosal healing and its relevance in IBD as well as discuss the mechanisms of IBD and potential strategies for altering these processes and inducing MH.
Keywords: Colitis; Inflammation; Injury/repair; Mucosal barrier; Mucosal healing; Therapeutics.
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Figures
References
-
- Pariente B, Hu S, Bettenworth D, Speca S, Desreumaux P, Meuwis MA, Danese S, Rieder F, Louis E. Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review. Clin Gastroenterol Hepatol. 2019;17:847–856. - PubMed
-
- de Sablet T, Potiron L, Marquis M, Bussière FI, Lacroix-Lamandé S, Laurent F. Cryptosporidium parvum increases intestinal permeability through interaction with epithelial cells and IL-1β and TNFα released by inflammatory monocytes. Cell Microbiol. 2016;18:1871–1880. - PubMed
-
- Bernink JH, Peters CP, Munneke M, te Velde AA, Meijer SL, Weijer K, Hreggvidsdottir HS, Heinsbroek SE, Legrand N, Buskens CJ, Bemelman WA, Mjösberg JM, Spits H. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14:221–229. - PubMed
-
- McDowell C, Farooq U, Haseeb M. Inflammatory Bowel Disease. 2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan- - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
